FDA Approves Pediatric Dose of Pancreatic Enzyme Supplement CREON
Originally posted in Cystic Fibrosis Foundation
Originally posted in Cystic Fibrosis Foundation
Jun
16
2011
16
2011
Jun
16
2011
16
2011
Jun
16
2011
16
2011
Lamellar Biomedical Secures Its First Orphan Drug Licence
Originally posted in Cystic Fibrosis News From Medical News Today
Glasgow biopharmaceutical firm, Lamellar Biomedical Ltd, launched four years ago to develop a new class of therapies for the prevention, treatment and control of severe respiratory disease, today announced that their lead clinical candidate LMS-611 for the treatment of patients with cystic fibrosis has received Orphan Drug Designation from the European Commission…
Jun
16
2011
16
2011
Altering Messenger RNA Holds Promise For Treating Cystic Fibrosis, Muscular Dystrophy, Cancer
Originally posted in Cystic Fibrosis News From Medical News Today
In a new study published in the journal Nature, scientists discovered an entirely new way to change the genetic code. The findings, though early, are significant because they may ultimately help researchers alter the course of devastating genetic disorders, such as cystic fibrosis, muscular dystrophy and many forms of cancer…
Jun
16
2011
16
2011
Abbott Receives FDA Approval For CREON
Originally posted in Cystic Fibrosis News From Medical News Today
Abbott (NYSE: ABT) announced that the U.S. Food and Drug Administration (FDA) has approved an infant-specific dose of CREON
by Raelene
